{"id":"https://openalex.org/W43670395","doi":null,"title":"Toxicity issues in cancer drug development.","display_name":"Toxicity issues in cancer drug development.","publication_year":2010,"publication_date":"2010-06-01","ids":{"openalex":"https://openalex.org/W43670395","mag":"43670395","pmid":"https://pubmed.ncbi.nlm.nih.gov/20496255"},"language":"en","primary_location":{"id":"pmid:20496255","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/20496255","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current opinion in investigational drugs (London, England : 2000)","raw_type":"Comment"},"volume":null,"type":"letter","indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5041168206","display_name":"David A. Gewirtz","orcid":"https://orcid.org/0000-0003-0437-4934","observed_orcids":["https://orcid.org/0000-0003-0437-4934"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"David A Gewirtz","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003165520","display_name":"Molly L. Bristol","orcid":"https://orcid.org/0000-0002-4259-8528","observed_orcids":["https://orcid.org/0000-0002-4259-8528"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Molly L Bristol","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5080340455","display_name":"Jack C. Yalowich","orcid":"https://orcid.org/0000-0001-5414-573X","observed_orcids":["https://orcid.org/0000-0001-5414-573X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jack C Yalowich","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":52,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"11","issue":"6","first_page":"612","last_page":"4"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":0.37869998812675476,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":0.37869998812675476,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":0.3765000104904175,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11235","display_name":"Statistical Methods in Clinical Trials","score":0.019700000062584877,"subfield":{"id":"https://openalex.org/subfields/2613","display_name":"Statistics and Probability"},"field":{"id":"https://openalex.org/fields/26","display_name":"Mathematics"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/anticancer-drug-development","display_name":"anticancer drug development","score":0.8360000252723694},{"id":"https://openalex.org/keywords/drug-toxicity","display_name":"drug toxicity","score":0.925000011920929},{"id":"https://openalex.org/keywords/targeted-therapy","display_name":"targeted therapy","score":0.6050000190734863},{"id":"https://openalex.org/keywords/hormone-antagonists","display_name":"hormone antagonists","score":0.6639999747276306},{"id":"https://openalex.org/keywords/monoclonal-antibodies","display_name":"monoclonal antibodies","score":0.9259999990463257},{"id":"https://openalex.org/keywords/imatinib","display_name":"imatinib","score":0.9919999837875366},{"id":"https://openalex.org/keywords/conventional-chemotherapy","display_name":"cytotoxic chemotherapy","score":0.7260000109672546},{"id":"https://openalex.org/keywords/predictive-toxicity-models","display_name":"predictive toxicity models","score":0.5120000243186951},{"id":"https://openalex.org/keywords/animal-models","display_name":"animal models","score":0.5260000228881836},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.7820000052452087},{"id":"https://openalex.org/keywords/drug-efficacy","display_name":"drug efficacy","score":0.42800000309944153},{"id":"https://openalex.org/keywords/signaling-pathways","display_name":"signaling pathways","score":0.5419999957084656},{"id":"https://openalex.org/keywords/druggable-targets","display_name":"druggable targets","score":0.7799999713897705}],"concepts":[{"id":"https://openalex.org/C10679952","wikidata":"https://www.wikidata.org/wiki/Q5308937","display_name":"Druggability","level":3,"score":0.7596195340156555},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6636478900909424},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.5674849152565002},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.553810715675354},{"id":"https://openalex.org/C2777583451","wikidata":"https://www.wikidata.org/wiki/Q177094","display_name":"Imatinib","level":3,"score":0.522782027721405},{"id":"https://openalex.org/C188198153","wikidata":"https://www.wikidata.org/wiki/Q1613840","display_name":"Limiting","level":2,"score":0.5087388157844543},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4955846071243286},{"id":"https://openalex.org/C64903051","wikidata":"https://www.wikidata.org/wiki/Q2198549","display_name":"Drug development","level":3,"score":0.422918438911438},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.4214918315410614},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.4202449917793274},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.18658408522605896},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.1781858503818512},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.16875576972961426},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.1477138102054596},{"id":"https://openalex.org/C127413603","wikidata":"https://www.wikidata.org/wiki/Q11023","display_name":"Engineering","level":0,"score":0.0},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0},{"id":"https://openalex.org/C78519656","wikidata":"https://www.wikidata.org/wiki/Q101333","display_name":"Mechanical engineering","level":1,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D002986","descriptor_name":"Clinical Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004353","descriptor_name":"Drug Evaluation, Preclinical","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true}],"locations_count":1,"locations":[{"id":"pmid:20496255","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/20496255","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current opinion in investigational drugs (London, England : 2000)","raw_type":"Comment"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.98580002784729,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"score":0.8500000238418579,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4235026439","https://openalex.org/W1999120252","https://openalex.org/W4244813758","https://openalex.org/W2473007551","https://openalex.org/W2112670558","https://openalex.org/W2013762709","https://openalex.org/W1493453469","https://openalex.org/W2037137341","https://openalex.org/W2135967092","https://openalex.org/W196606397"],"abstract_inverted_index":{"Cancer":[0],"chemotherapy":[1],"has":[2,102],"evolved":[3],"from":[4],"the":[5,22,46,65,87,93,109,155],"use":[6,47,110,156],"of":[7,24,48,67,95,111,135,157,169,178],"cytotoxic":[8],"drugs":[9,55,89],"that":[10,27,36,60,90],"are":[11,28,37,118],"accompanied":[12],"by":[13,70],"highly":[14],"deleterious":[15],"and":[16,35,54,148,183],"often":[17],"life-threatening":[18],"side":[19],"effects,":[20],"to":[21,45,82,145,174],"application":[23],"hormone":[25],"antagonists":[26],"more":[29,84],"specific":[30],"for":[31,64,98],"hormone-mediated":[32],"tumor":[33],"growth":[34],"generally":[38],"substantially":[39],"less":[40],"toxic":[41],"and,":[42],"most":[43],"recently,":[44],"targeted":[49],"therapies":[50],"including":[51],"humanized":[52],"mAbs":[53],"such":[56,100],"as":[57],"imatinib":[58],"(Gleevec)":[59],"have":[61,91,131],"been":[62,92,105],"developed":[63],"treatment":[66,97],"malignancies":[68],"induced":[69],"a":[71],"unique":[72],"chromosomal":[73],"rearrangement.":[74],"While":[75],"these":[76,116],"newer":[77,158],"agents":[78,113,117,159],"should":[79],"theoretically":[80],"prove":[81],"be":[83,162],"efficacious":[85],"than":[86],"conventional":[88],"foundation":[94],"cancer":[96],"decades,":[99],"improvement":[101],"not":[103],"always":[104],"demonstrated":[106],"either":[107],"with":[108,120],"single":[112],"or":[114,138,181],"when":[115],"combined":[119],"established":[121],"therapies.":[122],"Furthermore,":[123],"neither":[124],"cell":[125],"culture":[126],"nor":[127],"animal":[128],"model":[129],"systems":[130],"provided":[132],"reliable":[133],"predictions":[134],"drug":[136],"efficacy":[137,176],"toxicity.":[139],"Consequently,":[140],"despite":[141],"advancing":[142],"knowledge":[143],"relating":[144],"signaling":[146],"pathways":[147],"potential":[149],"druggable":[150],"targets":[151],"involved":[152],"in":[153],"cancer,":[154],"will":[160,171],"ultimately":[161],"dependent":[163],"on":[164],"empirical":[165],"clinical":[166],"trials,":[167],"many":[168],"which":[170],"likely":[172],"fail":[173],"demonstrate":[175],"because":[177],"pharmacokinetic":[179],"limitations":[180],"undesirable":[182],"limiting":[184],"patient":[185],"toxicities.":[186]},"counts_by_year":[{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":5},{"year":2022,"cited_by_count":7},{"year":2021,"cited_by_count":5},{"year":2020,"cited_by_count":5},{"year":2019,"cited_by_count":6},{"year":2018,"cited_by_count":5},{"year":2017,"cited_by_count":4},{"year":2016,"cited_by_count":5},{"year":2015,"cited_by_count":3},{"year":2014,"cited_by_count":2},{"year":2013,"cited_by_count":1},{"year":2012,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}